Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers

Laurent, Pascale; Anglès-Cano, Eduardo

doi:10.3324/haematol.2013.088948

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that endothelial and leukocyte-derived MPs served as a surface for the generation of plasmin by expressing urokinase-type plasminogen activator, its receptor and tissue plasminogen activator [36][37][38]. In view of these results, Plawinski and Angl es-Cano concluded that fibrinolytic hallmarks of MPs compensate the procoagulant activity [39]. Finally, our study includes a relatively small sample and was conducted in one medical center in Bydgoszcz (Poland).…”

Section: Discussionmentioning

confidence: 88%

Tissue‐factor‐bearing microparticles (MPs‐TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs‐TF generation

Świtońska

Słomka

Sinkiewicz

et al. 2014

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Tissue‐factor‐bearing microparticles (MPs‐TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs‐TF generation

Świtońska

Słomka

Sinkiewicz

et al. 2014

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…Activated PC subsequently inactivates factors Va and VIIIa [ 41 ]. Procoagulant effects of MPs are caused by binding of coagulation factors, mainly factors VII, IX, X, and prothrombin to the negatively charged phosphatidylserine on their surface [ 42 ] but MPs can also serve as contact membranes for the activation of fibrinolysis [ 43 ]. Fibrinolysis can occur when MPs derived from endothelial cells bearing uPA/urokinase-type plasminogen activator receptor (uPAR) get into contact with plasminogen that has been bound to platelets.…”

Section: Action Of Particles On Coagulationmentioning

confidence: 99%

Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation

Frőhlich

2016

CMC

View full text Add to dashboard Cite

Nanomaterials can get into the blood circulation after injection or by release from implants but also by permeation of the epithelium after oral, respiratory or dermal exposure. Once in the blood, they can affect hemostasis, which is usually not intended. This review addresses effects of biological particles and engineered nanomaterials on hemostasis. The role of platelets and coagulation in normal clotting and the interaction with the immune system are described. Methods to identify effects of nanomaterials on clotting and results from in vitro and in vivo studies are summarized and the role of particle size and surface properties discussed. The literature overview showed that mainly pro-coagulative effects of nanomaterials have been described. In vitro studies suggested stronger effects of smaller than of larger NPs on coagulation and a greater importance of material than of surface charge. For instance, carbon nanotubes, polystyrene particles, and dendrimers inferred with clotting independent from their surface charge. Coating of particles with polyethylene glycol was able to prevent interaction with clotting by some particles, while it had no effect on others and the more recently developed bio-inspired surfaces might help to design coatings for more biocompatible particles. The mainly pro-coagulative action of nanoparticles could present a particular risk for individuals affected by common diseases such as diabetes, cancer, and cardiovascular diseases. Under standardized conditions, in vitro assays using human blood appear to be a suitable tool to study mechanisms of interference with hemostasis and to optimize hemocompatibility of nanomaterials.

show abstract

“…An important characteristic is that all the proteins participants of the fibrinolytic mechanism are assembled on the fibrin surface. However, other alternative ways of fibrinolysis possibilities have been recently described; Mvs that transport tissue-type plasminogen activator (t-PA) or uPA can generate plasmin through plasminogen activation at their surface (Dejouvencel et al 2010;Plawinski and Angles-Cano 2013). Fibrinolytic Mvs promote cellular migration, angiogenesis, ECM degradation and a decrease in cellular adhesiveness (Lacroix et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer

Valente-Acosta¹,

Flores-García

González-Zárate

et al. 2020

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The fibrinolytic system plays an important role in breast cancer, favoring progression through extracellularmatrix degradation, angiogenesis, apoptosis and cellular proliferation. The expression of urokinase-type plasminogen activator (uPA) in breast cancer tissue is widely recognized as an unfavorable prognostic factor. However, fibrinolytic activity associated with uPA cannot be reliably measured in the blood because of the rapid inhibition of uPA by plasminogen activator inhibitor-1 (PAI-1). By contrast, circulating microvesicles (Mvs) in peripheral blood protect bound enzymes from inhibition. Mvs are extracellular vesicles, released from various types of cells, and their size fluctuates between 100 and 1,000 nm. Mvs carry DNA, RNA, miRNA, and proteins, thereby serving as a source of horizontal communication between cells. We investigated whether fibrinolytic activity on circulating Mvs reflects breast cancer progression. The study population consisted of 13 patients with breast cancer and 13 healthy women. The cancer patients included 4 patients in remission, 3 patients with locally advanced cancer, and 6 with metastatic disease. Mvs were isolated from peripheral blood, quantified by a protein concentration method, and their fibrinolytic potential was measured by their capacity to generate plasmin. Although the quantity of Mvs found in patients with cancer and healthy individuals was similar, plasmin generated on Mvs was twice the amount in patients with metastasis than in healthy women (P < 0.05), underlying the value of this distinctive parameter. The data suggest that in breast cancer patients, higher fibrinolytic activity of circulating Mvs could be related to progression and metastasis of breast cancer.

show abstract

Membrane microvesicles: a circulating source for fibrinolysis, new antithrombotic messengers

Cited by 3 publications

References 12 publications

Tissue‐factor‐bearing microparticles (MPs‐TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs‐TF generation

Tissue‐factor‐bearing microparticles (MPs‐TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs‐TF generation

Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation

Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer

Contact Info

Product

Resources

About